The Technical Analyst
Silk Road Medical Inc [SILK]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Silk Road Medical Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.06% $17.64
America/New_York / 26 apr 2024 @ 14:32
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 691.04 mill |
| EPS: | -1.440 |
| P/E: | -12.25 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 39.17 mill |
| Avg Daily Volume: | 0.746 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.25 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -12.25 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 16.71 - 18.59 ( +/- 5.32%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-05 | Ballinger Kevin J. | Buy | 11 700 | Common Stock |
| 2024-03-01 | Buchanan Lucas W. | Buy | 74 954 | Common Stock |
| 2024-03-05 | Buchanan Lucas W. | Sell | 9 877 | Common Stock |
| 2024-03-05 | Ruedy Richard | Sell | 3 800 | Common Stock |
| 2024-03-01 | Davis Andrew S. | Buy | 62 201 | Common Stock |
| INSIDER POWER |
|---|
| 87.76 |
| Last 99 transactions |
| Buy: 1 575 225 | Sell: 163 491 |
Forecast:
16:00 - $17.63
Live Trading Signals (every 1 min)
Forecast
1: 14:41 - $17.64
Forecast 2: 15:31 - $17.61
Forecast 3: 16:00 - $17.63
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $17.64 (-0.06% ) |
| Volume | 0.226 mill |
| Avg. Vol. | 0.746 mill |
| % of Avg. Vol | 30.25 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SILK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $16.67 | N/A | Active |
|---|
SILK
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Latest Press Releases
2024-04-23 16:30:00 - Press Release
Silk Road Medical To Present At The Bofa Securities 2024 Healthcare Conference
Sunnyvale, calif., april 23, 2024 (globe newswire) -- silk road medical, inc. (nasdaq: silk), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming bofa securities 2024 healthcare conference.
2024-04-09 16:30:00 - Press Release
Silk Road Medical To Report First Quarter 2024 Financial Results On April 30, 2024
Sunnyvale, calif., april 09, 2024 (globe newswire) -- silk road medical, inc. (nasdaq: silk), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on tuesday, april 30th, 2024. company management will host a corresponding audio webcast beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-04-02 16:30:00 - Press Release
Silk Road Medical Strengthens Tcar Portfolio With Launch Of Enroute Transcarotid Neuroprotection System Plus
Sunnyvale, calif., april 02, 2024 (globe newswire) -- silk road medical, inc. (nasdaq: silk), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its enroute ® transcarotid neuroprotection system plus (“nps plus”), a key component of the tcar® portfolio. this next generation device builds upon the prior enroute transcarotid neuroprotection system to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the tcar procedure.
2024-03-05 09:00:00 - Press Release
Silk Road Medical Expands Tcar® Portfolio With Launch Of Tapered Enroute® Transcarotid Stent System
Sunnyvale, calif., march 05, 2024 (globe newswire) -- silk road medical, inc. (nasdaq: silk), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its tapered enroute transcarotid stent system to hospitals in the united states. this launch expands upon the company's prior enroute transcarotid stent system, offering additional configurations to better tailor the transcarotid artery revascularization (tcar) procedure to patient anatomy. tcar is a minimally invasive, surgical procedure designed to provide best-in-class stroke protection while minimizing adverse events.
2024-02-28 16:05:00 - Press Release
Silk Road Medical Reports Fourth Quarter And Full Year 2023 Financial Results And provides 2024 Financial Outlook
Sunnyvale, calif., feb. 28, 2024 (globe newswire) -- silk road medical, inc. (nasdaq: silk), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended december 31, 2023.
Latest News
2024-04-23 16:30:00 - GlobeNewsWire
Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference
SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.
2024-04-23 13:00:26 - Zacks Investment Research
All You Need to Know About Silk Road Medical (SILK) Rating Upgrade to Buy
Silk Road Medical (SILK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-04-09 16:30:00 - GlobeNewsWire
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2024-04-08 11:25:15 - Zacks Investment Research
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
2024-03-22 13:01:08 - Zacks Investment Research
Silk Road Medical (SILK) Upgraded to Buy: What Does It Mean for the Stock?
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-03-07 08:56:07 - Zacks Investment Research
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
2024-02-28 23:24:07 - Seeking Alpha
Silk Road Medical, Inc (SILK) Q4 2023 Earnings Call Transcript
2024-02-28 19:21:04 - Zacks Investment Research
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.34 per share a year ago.
2024-02-07 16:30:00 - GlobeNewsWire
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2024-01-22 08:31:08 - Zacks Investment Research
Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.